Migraine: A review and future directions for treatment

Acta Neurologica Scandinavica

Volumn 114, Issue 2, 2006, Pages 71-83

  Linde, M ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Cephalea Headache Centre   (Sweden)

Author keywords

Compliance; Exercise; Future; Migraine; Natural course; Non pharmacological; Prophylaxis; Treatment; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMITRIPTYLINE; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DICLOFENAC; DOMPERIDONE; ERGOT ALKALOID; ESTROGEN; GABAPENTIN; IBUPROFEN; LISINOPRIL; MAGNESIUM; METHYSERGIDE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETASITES EXTRACT; PLANT EXTRACT; PROCHLORPERAZINE; RIBOFLAVIN; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; UBIDECARENONE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ACUPUNCTURE; AEROBIC EXERCISE; ALLODYNIA; ATTITUDE; BEHAVIOR THERAPY; BODY BURDEN; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; CHIROPRACTIC; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; EXPERIENCE; FREQUENCY ANALYSIS; HEALTH CARE COST; HEALTH INSURANCE; HEREDITY; HUMAN; LIFE; MASSAGE; MIGRAINE; MOLECULAR MECHANICS; MUSCLE RELAXATION; NAUSEA; NERVE EXCITABILITY; NEUROMODULATION; NEUROPHYSIOLOGY; NEUROPSYCHOLOGY; PAIN THRESHOLD; PATIENT COMPLIANCE; PETASITES; PHENOTYPE; PREMENSTRUAL SYNDROME; PREVALENCE; RECURRENT DISEASE; REVIEW; SENSORY STIMULATION; SKIN PAIN; TENSION HEADACHE; TIME SERIES ANALYSIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGE DISTRIBUTION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHAVIOR THERAPY; EXERCISE THERAPY; FEMALE; HUMANS; MALE; MANIPULATION, SPINAL; MIDDLE AGED; MIGRAINE DISORDERS; PREVALENCE; SEX DISTRIBUTION; TRYPTAMINES;

EID: 33745877952     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00670.x     Document Type: Review

References (142)

1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004;24(Suppl. 1):1-160.
2. SMETANA G. The diagnostic value of historical features in primary headache syndromes. Arch Intern Med 2000;160:2729-37.
3. BRUEHL S, LOFLAND K, Semenchuk E, Rokicki L, Penzien D. Use of cluster analysis to validate IHS diagnostic criteria for migraine and tension-type headache. Headache 1999;39:181-9.
4. LINDE M, DAHLÖF C. Attitudes and burden of disease among self-considered migraineurs. A nation-wide, population-based survey in Sweden. Cephalalgia 2004;24:455-65.
5. RASMUSSEN B, STEWART W. Epidemiology of migraine. In: Olesen J, Tfelt-Hansen P, Welch K, eds. The headaches, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2000;227-33.
6. DAHLÖF C, LINDE M. One-year prevalence of migraine in Sweden: a population-based study in adults. Cephalalgia 2001;21:664-71.
7. TERWINDT G, FERRARI M, TIJHUIS M, GROENEN S, PICAVET H, LAUNER L. The impact of migraine on quality of life in the general population. The GEM study. Neurology 2000;55:624-9.
8. WANG S-J, FUH J-L, LU S-R, JUANG K-D. Quality of life differs among headache diagnoses: analysis of SF-36 survey in 901 headache patients. Pain 2001;89:285-92.
9. TAKESHIMA T, ISHIZAKI K, FUKUHARA Y et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 2004;44:8-19.
10. HENRY P, MICHEL P, BROCHET B, DARTIGUES J, TISON S, SALAMON R. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992;12:229-37.
11. LIFTON R, STEWART W, DIAMOND S, DIAMOND M, REED M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57.
12. GOWERS W. A manual of diseases of the nervous system. London: J&A Churchill, 1888.
13. JACKSON H. Remarks on the diagnosis and treatment of diseases of the brain. Br Med J 1888;July 14:59-63.
14. LIVEING E. On megrim, sick-headache, and some allied disorders: a contribution to the pathology of nerve-storms. Nijmegen: Arts & Boeve, 1873 (Facsimile reprint 1997).
15. OLESEN J. Some clinical features of the acute migraine attack. An analysis of 750 patients. Headache 1978;18:268-71.
16. SACKS O. Migraine, 2nd edn. Köping: Brombergs Bokförlag AB, 1992.
17. SELBY G, LANCE W. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 1960;23:23-32.
18. BLAU J. Migraine prodromes separated from the aura: complete migraine. Br Med J 1980;281:658-60.
19. GIN N, RUGGIERO L, LIFTON R et al. Premonitory symptoms in migraine. An electronic diary study. Neurology 2003;60:935-40.
20. KELMAN L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 2004;44:865-72.
21. SMITH R, HASSE L, VONDER MEULEN M. Scalp and forearm tenderness during the different phases of the migraine cycle. Headache Care 2005;2:15-21.
22. ERIKSEN M, THOMSEN L, ANDERSEN I, NAZIM F, OLESEN J. Clinical characteristics of 362 patients with familial migraine with aura. Cephalalgia 2004;24:564-75.
23. JENSEN K, TFELT-HANSEN P, LAURITZEN M, OLESEN J. Classic migraine. A prospective recording of symptoms. Acta Neurol Scand 1986;73:359-62.
24. RUSSELL M, OLESEN J. A nosographic analysis of the migraine aura in a general population. Brain 1996;199:355-61.
25. LINDE M, MELLBERG A, DAHLÖF C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared to treated. Cephalalgia 2006;26:712-21.
26. CHRISTIANSEN V. Migrænen. En klinisk studie. Copenhagen: Levin & Munksgaard Forlag, 1927.
27. VANAGAITE J, PAREJA J, STØREN O, WHITE L, SAND T, STOVNER L. Light-induced discomfort and pain in migraine. Cephalalgia 1997;17:733-41.
28. VANAGAITE VINGEN J, PAREJA J, STØREN O, WHITE L, STOVNER L. Phonophobia in migraine. Cephalalgia 1998;18:243-9.
29. BLAU J. Migraine postdromes: symptoms after attacks. Cephalalgia 1991;11:229-31.
30. MULDER E, LINSSEN W, PASSCHIER J, ORLEBEKE J, DE GEUS E. Interictal and postictal cognitive changes in migraine. Cephalalgia 1999;19:557-65.
31. MEYER J, THORNBY J, CEAWFORD K, RAUCH G. Reversible cognitive decline accompanies migraine and cluster headache. Headache 2000;40:638-46.
32. CALANDRE E, BEMBIBRE J, ARNEDO A, BECERRA D. Cognitive disturbances and regional cerebral blood flow abnormalities in migraine patients: their relationship with the clinical manifestations of the illness. Cephalalgia 2002;22:291-302.
33. EVERS S, RÜSSENSCHMIDT J, FRESE A, RAHMANN A, HUSSTEDT I-W. Impact of antimigraine compounds on cognitive processing: a placebo-controlled crossover study. Headache 2003;43:1102-8.
34. AROMAA M, RAUTAVA P, SILLANPAA M, HELENIUS H, OJANLATVA A. Familial occurrence of headache. Cephalalgia 1999;25:49-52.
35. KORS E, VANMOLKOT K, HAAN J, FRANTS R, VAN DEN MAAGDENBERG A, FERRARI M. Recent findings in headache genetics. Curr Opin Neurol 2004;17:283-8.
36. WELCH K. Contemporary concepts of migraine pathogenesis. Neurology 2003;61(8 Suppl. 4):2-8.
37. BOSKA M, WELCH K, BARKER P, NELSON J, SCHULTZ L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 2002;58:1227-33.
38. SANDOR P, AFRA J, PROIETTI CECCHINI A, ALBERT A, SCHOENEN J. From neurophysiology to genetics: cortical information processing in migraine underlies familial influences - a novel approach. Funct Neurol 2005;3:68-72.
39. KNIGHT Y, BARTSCH T, KAUBE H, GOADSBY P. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 2002;22:RC213.
40. LINDE M, DAHLÖF C. Menstrual migraine: clinical considerations. Rev Ser Neurol 2002;4-8:24.
41. AMBROSINI A, DE NOORDHOUT A, SANDOR P, SCHOENEN J. Electrophysiological studies in migraine: a comprehensive review of their interest and limitations. Cephalalgia 2003;23:13-31.
42. WAEBER C, MOSKOWITZ M. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 2003;61(8 Suppl. 4):9-20.
43. DRUMMOND P. Scalp tenderness and sensitivity to pain in migraine and tension headache. Headache 1987;27:45-50.
44. DRUMMOND P. Motion sickness and migraine: optokinetic stimulation increases scalp tenderness, pain sensitivity in the fingers and photophobia. Cephalalgia 2002;22:117-24.
45. KOWACS P, PIOVESAN E, WERNECK L et al. Influence of intense light stimulation on trigeminal and cervical pain perception thresholds. Cephalalgia 2001;21:184-8.
46. CHRONICLE E, MULLENERS W. Visual system dysfunction in migraine: a review of clinical and psychophysical findings. Cephalalgia 1996;16:525-35.
47. SANDOR P, MASCIA A, SEIDEL L, DE PASCUA V, SCHOENEN J. Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann Neurol 2001;49:668-72.
48. ROSSI C, ALBERT A, SARCHIELLI P et al. Balance disorders in headache patients: evaluation by computerized static stabilometry. Acta Neurol Scand 2005;111:407-13.
49. HANSSON E, MUYDERMAN H, LEONOVA J et al. Astroglia and glutamate in physiology and pathology: aspects on glutamate transport, glutamate-induced cell swelling and gap-junction communication. Neurochem Int 2000;37:317-29.
50. BENARROCH E. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin Proc 2005;80:1326-38.
51. WEILLER C, MAY A, LIMMROTH V et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-60.
52. AFRIDI S, GIN N, KAUBE H et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol 2005;62:1270-5.
53. LAURITZEN M, OLSEN T, LASSEN N, PAULSON O. Regulation of regional cerebral blood flow during and between migraine attacks. Ann Neurol 1983;14:569-72.
54. SANCHEZ DEL RIO M, REUTER U. Migraine aura: new information on underlying mechanisms. Curr Opin Neurol 2004;17:289-93.
55. GORJI A. Spreading depression: a review of the clinical relevance. Brain Res Brain Res Rev 2001;38:33-60.
56. BLOMSTRAND F, KHATIBI S, MUYDERMAN H, HANSSON E, OLSSON T, RONNBACK L. 5-Hydroxytryptamine and glutamate modulate velocity and extent of intercellular calcium signalling in hippocampal astroglial cells in primary culture. Neuroscience 1999;88:1241-53.
57. LEIBOWITZ D. The glial spike theory. I. On an active role of neuroglia in spreading depression and migraine. Proc Biol Sci 1992;250:287-95.
58. WOODS R, IACOBONI M, MAZZIOTTA J. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headaches. N Engl J Med 1994;331:1689-92.
59. RAY B, WOL H. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-56.
60. NICHOLS FI, MAWAD M, MOHR J, STEIN B, HILAL S, MICHELSEN J. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke 1990;21:555-9.
61. OLESEN J, FRIBERG L, OLSEN T et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990;28:791-8.
62. MAY A, BUCHEL C, TURNER R, GOADSBY P. Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J Cereb Blood Flow Metab 2001;21:1171-6.
63. KRUUSE C, THOMSEN L, BIRK S, OLEESEN J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003;126:241-7.
64. EDVINSSON L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs 2001;15:745-53.
65. MAY A, SHEPHEARD S, KNORR M et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 1998;121(Pt 7):1231-7.
66. HAMEL E. The biology of serotonin receptors: focus on migraine pathophysiology and treatment. Can J Neurol Sci 1999;26(Suppl. 3):2-6.
67. SANYA E, BROWN C, VON WILMOWSKY C, NEUNDÖRFER B, HILZ M. Impairment of parasympathetic baroreflex responses in migraine patients. Acta Neurol Scand 2005;111:102-7.
68. LIPTON R, STEWART W, LIBERMAN J. Self-awareness of migraine: interpreting the labels that headache sufferers apply to their headaches. Neurology 2002;58(Suppl. 6):21-6.
69. DAHLÖF C, DIMENÄS E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995;15:31-6.
70. STEINER T. Headache burdens and bearers. Funct Neurol 2000;15(Suppl. 3):219-23.
71. LIPTON R, BIGAL M, KOLODNER K, STEWART W, LIBERMAN J, STEINER T. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia 2003;23:429-40.
72. FISHMAN P, BLACK L. Indirect costs of migraine in a managed care population. Cephalalgia 1999;19:50-7.
73. STANG P, CARSON A, ROSE K et al. Headache, cerebrovascular symptoms, and stroke. Neurology 2005;64:1573-7.
74. SOCHURKOVA D, MOREAU T, LEMESLE M, MENASSA M, GIROUD M, DUMAS R. Migraine history and migraine-induced stroke in the Dijon stroke registry. Neuroepidemiology 1999;18:85-91.
75. TFELT-HANSEN P, HENRY P, MULDER L, SCHELDEWAERT R, SCHOENEN J, CHAZOT G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-6.
76. DIENER H, BUSSONE G, DE LIANO H, EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24:947-54.
77. ROSS-LEE L, EADIE M, HEAZLEWOOD V, BOCHNER F, TYRER J. Aspirin pharmakokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983;24:777-85.
78. SCHULMAN E, DERMOTT K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003;43:729-33.
79. BROGDEN R, CARMINE A, HEEL R, SPEIGHT T, AVERY G. Domperidone. A review of its pharmacological activity, pharmakokinetics and therapeutic efficacy in symptomatic treatment of chronic dyspepsia and as an anti-emetic. Drugs 1982;24:360-400.
80. JONES J, SKLAR D, DOUGHERTY J, WHITE W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. J Am Med Assoc 1989;261:1174-6.
81. MACGREGOR E, WILKINSON M, BANCROFT K. Domperidone plus paracetamol in the treatment of migraine headache. Cephalalgia 1993;13:124-7.
82. SHARMA S, PRASAD A, NEHRU R, ANAND K, RISHI R, CHATURVEDI S. Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine. Headache 2002;42:896-902.
83. ELLIS G, DELANEY J, DEHART D, OWENS A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993;22:191-5.
84. CHRISTIE S, GÖBEL H, MATEOS V, ALLEN C, VRIJENS F, SHIVAPRAKASH M. Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003;49:20-9.
85. DIENER H, RECHES A, PASCUAL J, PITEI D, STEINER T. Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002;47:99-107.
86. EVERS S, GRALOW I, BAUER B et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiological study. Neuropharmacology 1999;22:201-6.
87. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75.
88. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992;32:177-84.
89. GERAUD G, COMPAGNON A, ROSSI A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002;47:88-98.
90. EVERS S, AFRA J, FRESE A et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006;13:560-72.
91. HOUGHTON L, FOWLER P, KEENE O, READ N. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992;6:685-91.
92. CIPOLLA G, SACCO S, CREMA F, MORO E, DE PONTI F, FRIGO G. Gastric motor effects of triptans: open questions and future perspectives. Pharmacol Res 2001;43:205-10.
93. TACK J, COULIE B, WILMER A, ANDRIOLI A, JANSSENS J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000;46:468-73.
94. DAHLÖF C, LINDE M, KEREKES E. Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice. J Headache Pain 2004;5:237-42.
95. BATES D, ASHFORD E, DAWSON R et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44:1587-92.
96. OLESEN J, DIENER H, SCHOENEN J, HETTIARACHCHI J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004;11:671-7.
97. LINDE M, MELLBERG A, DAHLÖF C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006;26:113-21.
98. 1B/1D-agonist) causes a transient allodynia. Cephalalgia 2004;24:1057-66.
99. LINTON-DAHLÖF P, LINDE M, DAHLÖF C. Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study. Cephalalgia 2000;20:658-62.
100. LINDE M, FJELL A, CARLSSON J, DAHLÖF C. Role of the needling per se in acupuncture as prophylaxis for menstrually related migraine: a randomized placebo-controlled study. Cephalalgia 2005;25:41-7.
101. HOLROYD K, PENZIEN D, CORDINGLEY G. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991;31:333-40.
102. GAWEL M, KREEFT J, NELSON R, SIMARD D, ARNOTT W. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992;19:340-5.
103. DIENER H, MATIAS-GUIU J, HARTUNG E et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002;22:209-21.
104. FREITAG F, COLLINS S, CARLSON H et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-9.
105. BRANDES J, SAPER J, DIAMOND M et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73.
106. DIENER H, TFELT-HANSEN P, DAHLÖF C et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50.
107. MEI D, CAPUANO A, VOLLONO C et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 2004;25:245-50.
108. ZIEGLER D, HURWITZ A, HASSANEIN R, KODANAZ H, PRESKORN S, MASON J. A comparison of propranolol and amitriptyline. Arch Neurol 1987;44:486-9.
109. ZIEGLER D, HURWITZ A, PRESKORN S, HASSANEIN R, SEIM J. Propranolol and amitriptyline in prophylaxis of migraine: pharmacokinetic and therapeutic effects. Arch Neurol 1993;50:825-30.
110. LIPTON R, GOBEL H, EINHAUPL K, WILKS K, MAUSKOP A. Petasites hybridus root (butterbur) is an effective treatment for migraine. Neurology 2004;63:2240-4.
111. TRONVIK E, STOVNER L, HELDE G, SAND T, BOVIM G. Prophylactic treatment of migraine with an angiotensin II receptor blocker. A randomized controlled trial. JAMA 2002;289:65-9.
112. SANDOR P, DI CLEMENTE L, COPPOLA G, SAENGER U, FUMAL A, MAGIS D. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005;64:713-5.
113. MATHEW N, RAPOPORT A, SAPER J et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-28.
114. SCHRADER H, STOVNER L, HELDE G, SAND T, BOVIM G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. Br Med J 2001;322:1-19.
115. PFAENRATH V, WESSELY P, MEYER C et al. Magnesium in the prophylaxis of migraine - a double-blind, placebo-controlled study. Cephalalgia 1996;16:436-40.
116. PEIKERT A, WILIMZIG C, KÖHNE-VOLLAND R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16:257-63.
117. SILBERSTEIN S. Methysergide. Cephalalgia 1998;18:421-35.
118. SCHOENEN J, JACQUY J, LENAERTS M. Effectiveness of high-dose riboflavin in migraine prophylaxis - a randomized controlled trial. Neurology 1998;50:466-70.
119. RAHIMTOOLA H, BUURMA H, TIJSSEN C, LEUFKENS H, EGBERTS A. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia 2003;23:293-301.
120. AUBÉ M. Improving patient compliance to prophylactic migraine therapy. Can J Neurol Sci 2002;29(Suppl. 2):40-3.
121. PETERS M, HUIJER ABU-SAAD H, VYDELINGUM V, DOWSON A, MURPHY M. Patients' decision-making for migraine and chronic daily headache management. A qualitative study. Cephalalgia 2003;23:833-41.
122. MACGREGOR E. The doctor and the migraine patient: improving compliance. Neurology 1997;48(Suppl. 3):16-20.
123. HOLROYD K, PENZIEN D, LIPCHIK G. Behavioral management of headache. In: Silberstein S, Lipton R, Dalessio D, eds. Wolff's headache and other head pain, 7th edn. Oxford: Oxford University Press, 2001:562-98.
124. SANDOR P, AFRA J. Nonpharmacologic treatment of migraine. Curr Pain Headache Rep 2005;9:202-5.
125. REID G, MCGRATH P. Psychological treatments for migraine. Biomed Pharmacother 1996;50:58-63.
126. MCGRATH P, HOLROYD K, SORBI M. Psychological and behavioral treatments of migraine. In: Olesen J, Tfelt-Hansen P, Welch K, eds. The headaches, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2000;371-8.
127. LINDE M, MAY A, LIMMROTH V, DAHLÖF C. Ethical aspects of placebo in migraine research. Cephalalgia 2003;23:491-5.
128. HERMANN C, KIM M, BLANCHARD E. Behavioral and prophylactic pharmacological intevention studies of pediatric migraine: an exploratory meta-analysis. Pain 1995;60:239-56.
129. LARSSON B, CARLSSON J, FICHTEL Å, MELIN L. Relaxation treatment of adolescent headache sufferers: results from a school-based replication series. Headache 2005;45:692-704.
130. MARCUS D, SCHAR L, MERCER S, TURK D. Nonpharmacological treatment of migraine: incremental utility of physical therapy with relaxation and thermal feedback. Cephalalgia 1998;18:266-72.
131. LOCKET D, CAMPBELL J. The effects of aerobic exercise on migraine. Headache 1992;32:50-4.
132. DARLING M. Exercise and migraine. J Sports Med Phys Fitness 1991;31:294-302.
133. KÖSEOGLU E, AKBOYRAZ A, SOYUER E, ERSOY A. Aerobic exercise and plasma beta endorphin levels in patients with migrainous headache without aura. Cephalalgia 2003;23:972-6.
134. OSÜN NARIN S, PINAR L. The effects of exercise and exercise-related changes in blood nitric oxide level on migraine headache. Clin Rehabil 2003;17:624-30.
135. LEMSTRA M, STEWART B, OLSZYNSKI W. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache 2002;42:845-54.
136. VINCENT C. A controlled trial of the treatment of migraine by acupuncture. Clin J Pain 1989;5:305-12.
137. HESSE J, MÖGELVANG B, SIMONSEN H. Acupuncture versus metoprolol in migraine prophylaxis: a randomised trial of trigger point inactivation. J Intern Med 1994;235:451-6.
138. ALLAIS G, DE LORENZO C, QUIRICO P et al. Acupuncture in the prophylactic treatment of migraine without aura: a comparison with flunarizine. Headache 2002;42:855-61.
139. MELCHART D, LINDE K, FISCHER P et al. Acupuncture for idiopathic headache (Cochrane review). Issue 4 ed: Update Software, 2002.
140. LINDE K, STRENG A, JÜRGENS S et al. Acupuncture for patients with migraine. A randomized controlled trial. JAMA 2005;293:2118-25.
141. BIONDI D. Physical treatments for headache: a structured review. Headache 2005;45:738-46.
142. BRONFORT G, NILSSON N, ASSENDELFT WJJ et al. Noninvasive physical treatments for chronic headache. Cochrane Database Syst Rev 1999;4:CD001878.